Master Kong's beverages business first-half revenue down 4.09% year-on-year
Master Kong Holdings recently released its interim results for 2020, and as of June 30 this year, the company's revenue rose 8% year-on-year to $32.934 billion and net profit was $2.653 billion, up 47.26% year-on-year.
In the first half of the year, the operating income of Master Kong Beverage was 17.617 billion yuan, accounting for 53.49% of the total income, a decrease of 750 million yuan, or 4.09% less than the same period last year. Thanks to the improvement in gross profit margin, a year-on-year decrease in other operating expenses and a decrease in minority interests, profit attributable to shareholders of the beverage business company rose 18.73% year-on-year to 838 million yuan.
With the epidemic under control, the rebound trend of the beverage business from the second quarter onwards was obvious. Among them, Master of tea ready to drink from the second quarter to increase brand investment efforts to enhance the brand appeal to young consumers and family consumer groups.
2026-10-18
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Is Evonik’s Massive Global Expansion of Hydroxyl-Terminated Polybutadiene (HTPB) a Technological Ambition — or a Geopolitical Gamble?
-
Wanhua’s Counter-Cyclical Expansion: A Gamble or a Strategic Move for the Next Cycle?
-
Yulong Petrochemical’s 100,000-ton MMA Project Comes Online Amid a “Deep V-Shaped Rebound” — Opportunity or Hidden Risk?
-
Behind Starbucks China’s Ownership Change: The Race for Localization and Efficiency
-
Huafon Chemical Plans RMB 6.85 Billion Acquisition to Expand Its TPU and PU Resin Portfolio
-
CordenPharma Invests €80 Million to Raise Sterile Injectable Capacity to 500 Million Units Annually
-
ZPC Plans 1.2 Million-Tonne PDH Unit, Setting a New Global Licensing Record
-
McKinsey Pays to Close a Purdue Liability Chapter
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Iran Conflict Leaves a Long Shadow on Drug Supply
Recommend Reading
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
-
$2.43 Billion Deal: Olin Buys Huntsman
-
Evonik Cuts 3,200 Jobs: Europe’s Chemical Winter Is Not Over
-
INEOS Closes US Polystrene Plant: 400K Tons of PD in the US Can't Hold On
-
BASF Ludwigshafen Workforce Falls Below 30,000, Lowest Level in 72 Years
-
Polyethylene Weakens with Fluctuations, Trading Remains Light Before the Chinese New Year
-
Returning to Fundamentals: Ethylene Glycol Prices in April Show Volatile and Weak Trends
-
Applications and Safety of Sodium Dichromate
-
Recent Continuous Decline in the Ethyl Acetate Market in China
-
Notice of 2026 Chinese New Year Holiday